Sort   by:  
 Page size 
GenomicsMAPK-related gene signature predicting MAPKi sensitivity in pLGG - McGill cohort
MAPK-related gene signature predicting MAPKi sensitivity in pLGG - McGill cohort
PRJNA921881 | ENA
GenomicsMAPK-related gene signature predicting MAPKi sensitivity in pLGG - Charite cohort
MAPK-related gene signature predicting MAPKi sensitivity in pLGG - Charite cohort
PRJNA921878 | ENA
GenomicsRebound after MAPK inhibitor withdrawal in pLGG cells
Rebound after MAPK inhibitor withdrawal in pLGG cells
PRJNA1050234 | ENA
TranscriptomicsMAPK-related gene signature predicting MAPKi sensitivity in pLGG - McGill cohort
MAPK inhibitor sensitivity scores (MSS) were developed to predict sensitivity to MAPK inhibitors in pediatric low-grade gliomas (pLGG). The scores were validated in pLGG cell lines in vitro and in the publicly available Open Pediatric Brain Tumor Atlas dataset. Validation in independent datasets is ...
ORGANISM(S): Homo sapiens 
2023-06-28 | GSE222405 | GEO
TranscriptomicsMAPK-related gene signature predicting MAPKi sensitivity in pLGG - Charite cohort
MAPK inhibitor sensitivity scores (MSS) were developed to predict sensitivity to MAPK inhibitors in pediatric low-grade gliomas (pLGG). The scores were validated in pLGG cell lines in vitro and in the publicly available Open Pediatric Brain Tumor Atlas dataset. Validation in independent datasets is ...
ORGANISM(S): Homo sapiens 
2023-06-28 | GSE222404 | GEO
TranscriptomicsRebound after MAPK inhibitor withdrawal in pLGG cells
An in vitro MAPK inhibitor withdrawal rebound model was generated using the patient-derived, PXA-like cell line BT-40 (BRAFV600E, CDKN2Adel). Using this model, we investigated potential cellular intrinsic and extrinsic mechanisms involved in rebound growth in pLGG through multi-omics analysis (RNAse...
ORGANISM(S): Homo sapiens 
2024-04-17 | GSE249718 | GEO
ProteomicsRebound after MAPK inhibitor withdrawal in pLGG cells
An in vitro MAPK inhibitor withdrawal rebound model was generated using the patient-derived, PXA-like cell line BT-40 (BRAFV600E, CDKN2Adel). Using this model, we investigated potential cellular intrinsic and extrinsic mechanisms involved in rebound growth in pLGG through multi-omics analysis (RNAse...
ORGANISM(S): Homo sapiens (Human) 
2024-04-17 | PXD048277 | Pride
Proteomic analysis Phosphoproteomic analysis Treatment withdrawal Mapk inhibitor Pediatric low-grade glioma 
GenomicsMAPK-related gene signature predicting MAPKi sensitivity in pLGG
MAPK-related gene signature predicting MAPKi sensitivity in pLGG
PRJNA921876 | ENA
UnknownMAPK inhibitor sensitivity scores predict sensitivity driven by the immune infiltration in pediatric low-grade gliomas.
Not available
S-EPMC10374577 | biostudies-literature
ProteomicsMolecular analysis of brain tumour models
Pilocytic astrocytomas and other paediatric low-grade gliomas (pLGGs) are often considered single-pathway diseases due to the predominance of MAPK/ERK pathway alterations observed in these patients. However, emerging evidence suggests that the MAPK/ERK interacts within a complex signalling network t...
ORGANISM(S): Homo sapiens (Human) 
2025-05-14 | PXD060246 | Pride
Kiaa1549 Label-free proteomics Mapk Braf Plgg Phosphoproteomics Fgfr Lc-ms/ms 
Sort   by:  
 Page size